Copy number analysis of ductal carcinoma in situ with and without recurrence

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Modern Pathology

• Publication date

  2015-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/modpathol.2015.75PMID 26321097
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment

  2014cited by this paper
• An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer

  2013cited by this paper
• A review of the management of ductal carcinoma in situ following breast conserving surgery.

  2013cited by this paper
• Comprehensive molecular portraits of human breast tumours

  2013cited by this paper
• Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial.

  2013cited by this paper
• Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study

  2013cited by this paper
• The nuclear coactivator Amplified In Breast Cancer 1 maintains tumor initiating cells during development of Ductal Carcinoma In Situ

  2013cited by this paper
• Emerging landscape of oncogenic signatures across human cancers

  2013cited by this paper
• Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery.

  2013cited by this paper
• Differential copy number aberrations in novel candidate genes associated with progression from in situ to invasive ductal carcinoma of the breast

  2012cited by this paper
• Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra‐tumour genetic heterogeneity and clonal selection

  2012cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ

  2012cited by this paper
• Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome

  2012cited by this paper
• Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma

  2012cited by this paper
• The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression.

  2012cited by this paper
• Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma

  2012cited by this paper
• Copy Number Imbalances between Screen- and Symptom-Detected Breast Cancers and Impact on Disease-Free Survival

  2011cited by this paper
• Paradoxical relationship between chromosomal instability and survival outcome in cancer.

  2011cited by this paper
• Outcomes of Screening-Detected Ductal Carcinoma In Situ Treated with Wide Excision Alone

  2011cited by this paper
• Genomic alterations and phenotype of large compared to small high-grade ductal carcinoma in situ.

  2011cited by this paper
• Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.

  2010cited by this paper
• TrkC plays an essential role in breast tumor growth and metastasis.

  2010cited by this paper
• Breast cancer precursors revisited: molecular features and progression pathways

  2010cited by this paper
• Allele-specific copy number analysis of tumors

  2010cited by this paper
• Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization

  2009cited by this paper
• Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer

  2008cited by this paper
• Analysis of molecular inversion probe performance for allele copy number determination

  2007cited by this paper
• Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy

  2006cited by this paper
• Novel patterns of genome rearrangement and their association with survival in breast cancer.

  2006cited by this paper
• Genomic Instability and Prognosis in Breast Carcinomas

  2006cited by this paper
• The natural history of low‐grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long‐term follow‐up

  2005cited by this paper
• Mutation of GATA3 in human breast tumors

  2004cited by this paper
• Patterns of Chromosomal Alterations in Breast Ductal Carcinoma In situ

  2004cited by this paper
• Ductal carcinoma in situ, complexities and challenges.

  2004cited by this paper
• The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells.

  2001cited by this paper
• Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences.

  2000cited by this paper
• Comparative genomic hybridization of ductal carcinoma in situ of the breast—evidence of multiple genetic pathways

  1999cited by this paper
• Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

  1999cited by this paper
• Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type

  1999cited by this paper
• Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation

  1998cited by this paper
• AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.

  1997cited by this paper
• Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.

  1992cited by this paper
• DNA content and survival in mammary carcinoma.

  1980cited by this paper

• Decoding tumor-infiltrating lymphocytes heterogeneity in ductal carcinoma in situ: immune microenvironment dynamics and prognostic insights

  2025influential citation
• Phylogenetic analysis of paired breast carcinomas identifies genetic events associated with clonal recurrence and invasive progression

  2025cites this paper
• Deep learning-based risk stratification of ductal carcinoma in situ using mammography and abbreviated breast magnetic resonance imaging

  2025cites this paper
• Filtering cells with high mitochondrial content depletes viable metabolically altered malignant cell populations in cancer single-cell studies

  2025cites this paper
• Biomarkers Predicting Progression and Prognosis of Ductal Carcinoma In Situ (DCIS)

  2025influential citation
• Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.

  2024cites this paper
• Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance

  2024cites this paper
• Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance

  2024cites this paper
• Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer

  2024cites this paper
• Tumor microenvironmental determinants of high-risk DCIS progression

  2024cites this paper
• A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression

  2023cites this paper
• Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study

  2023cites this paper
• Unifying comprehensive genomics and transcriptomics in individual cells to illuminate oncogenic and drug resistance mechanisms

  2023cites this paper
• MIND the translational gap: Preclinical models of ductal carcinoma in situ

  2023cites this paper
• Archival single-cell genomics reveals persistent subclones during DCIS progression.

  2023cites this paper
• Unifying genomics and transcriptomics in single cells with ResolveOME amplification chemistry to illuminate oncogenic and drug resistance mechanisms

  2022cites this paper
• Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts.

  2022cites this paper
• Identifying recurrences and metastasis after ductal carcinoma in situ (DCIS) of the breast

  2022cites this paper
• Exploration of the breast ductal carcinoma in situ signature and its prognostic implications

  2022cites this paper
• Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer

  2022cites this paper
• Ductal Carcinoma in Situ: Molecular Changes Accompanying Disease Progression

  2022cites this paper
• Evaluating statistical approaches to define clonal origin of tumours using bulk DNA sequencing: context is everything

  2022cites this paper
• The 5-Year Paradigm in DCIS of the Breast: Unexpected Lessons From the NSABP B-43 Trial.

  2021cites this paper
• Genomic profiling defines variable clonal relatedness between invasive breast cancer and primary ductal carcinoma in situ

  2021cites this paper
• DCIS genomic signatures define biology and clinical outcome: Human Tumor Atlas Network (HTAN) analysis of TBCRC 038 and RAHBT cohorts

  2021cites this paper
• Exploration of Core Genes Signature and Prognostic Implication for Ductal Carcinoma In Situ of the Breast

  2021cites this paper
• Local Recurrence after Treatment of Ductal Carcinoma In Situ: A Comprehensive Overview.

  2021cites this paper
• Genomic Alterations during the In Situ to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System

  2020influential citation
• Chromosomal microarray analysis of benign mesenchymal tumors with RB1 deletion.

  2020cites this paper
• The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma

  2020cites this paper
• Transcriptome and genome evolution during HER2-amplified breast neoplasia

  2020cites this paper
• Breast Pathology

  2020cites this paper
• Ductal carcinoma in situ of breast: update 2019.

  2019cites this paper
• Ductal carcinoma in situ: to treat or not to treat, that is the question

  2019cites this paper
• Genomic landscape of ductal carcinoma in situ and association with progression

  2019cites this paper
• A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast

  2019cites this paper
• Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma

  2019cites this paper
• Chromosomal Microarray in the New High-Throughput Technological and Bioinformatic Era

  2019cites this paper
• The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer

  2019cites this paper
• Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape

  2018cites this paper
• Thioredoxin-interacting protein is an independent risk stratifier for breast ductal carcinoma in situ

  2018cites this paper
• Thioredoxin Interacting Protein (TXNIP) is an Independent Risk Stratifier for Breast Ductal Carcinoma in situ

  2018cites this paper
• Thioredoxin interacting protein (TXNIP) is an independent risk stratifier for breast ductal carcinoma in situ. Modern Pathology . ISSN 1530-0285

  2018cites this paper
• INVESTIGATING INVASION IN DUCTAL CARCINOMA IN SITU WITH TOPOGRAPHICAL SINGLE CELL GENOME SEQUENCING

  2018cites this paper
• Using low-coverage whole genome sequencing technique to analyze the chromosomal copy number alterations in the exfoliative cells of cervical cancer

  2018cites this paper
• Ductal Carcinoma In Situ Biology, Biomarkers, and Diagnosis

  2017influential citation
• Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer

  2017cites this paper
• Utilization of the oncoscan microarray assay in cancer diagnostics

  2017cites this paper
• Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features

  2017cites this paper
• Genome evolution in ductal carcinoma in situ: invasion of the clones

  2017cites this paper
• Biomarkers in ductal carcinoma in situ

  2016cites this paper
• Recurrent amplification of RTEL1 and ABCA13 and its synergistic effect associated with clinicopathological data of gastric adenocarcinoma

  2016cites this paper
• Catalog of genetic progression of human cancers: breast cancer

  2016cites this paper
• Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue

  2016cites this paper